| Net Loss per Share |
Note 9: Net Loss per Share
The following table provides the computation of basic and diluted net loss per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
|
(in thousands, except per share data) |
| Numerator–basic: |
|
|
|
|
|
|
|
| Net loss attributable to Class A common stockholders–basic |
$ |
(13,296) |
|
|
$ |
(11,173) |
|
|
$ |
(32,311) |
|
|
$ |
(176,100) |
|
| Numerator–diluted: |
|
|
|
|
|
|
|
| Net loss attributable to Class A common stockholders–basic |
$ |
(13,296) |
|
|
$ |
(11,173) |
|
|
$ |
(32,311) |
|
|
$ |
(176,100) |
|
| Effective of dilutive securities: |
|
|
|
|
|
|
|
| Shares of Class V common stock |
(23,993) |
|
|
(54,156) |
|
|
(85,008) |
|
|
(853,125) |
|
| Net loss attributable to Class A common stockholders–diluted |
$ |
(37,289) |
|
|
$ |
(65,329) |
|
|
$ |
(117,319) |
|
|
$ |
(1,029,225) |
|
| Denominator–basic: |
|
|
|
|
|
|
|
| Weighted average Class A common shares outstanding–basic |
114,198 |
|
|
41,579 |
|
|
88,010 |
|
|
41,579 |
|
| Net loss per share attributable to Class A common stockholders–basic |
$ |
(0.12) |
|
|
$ |
(0.27) |
|
|
$ |
(0.37) |
|
|
$ |
(4.24) |
|
| Denominator–diluted: |
|
|
|
|
|
|
|
| Weighted average Class A common shares outstanding–basic |
114,198 |
|
|
41,579 |
|
|
88,010 |
|
|
41,579 |
|
| Weighted average effect of dilutive securities: |
|
|
|
|
|
|
|
| Shares of Class V common stock |
198,481 |
|
|
201,457 |
|
|
200,369 |
|
|
199,684 |
|
| Weighted average shares outstanding–diluted |
312,679 |
|
|
243,036 |
|
|
288,379 |
|
|
241,263 |
|
| Net loss per share attributable to Class A common stockholders–diluted |
$ |
(0.12) |
|
|
$ |
(0.27) |
|
|
$ |
(0.41) |
|
|
$ |
(4.27) |
|
Shares of Class V common stock do not share in the earnings or losses of P3 Health Partners, Inc. and are therefore not participating securities. As such, separate presentation of basic and diluted net income per share for Class V common stock under the two-class method is not required. The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
|
(in thousands) |
Stock warrants (1)
|
81,938 |
|
|
10,819 |
|
|
81,938 |
|
|
10,819 |
|
Stock options (1)
|
5,867 |
|
|
2,134 |
|
|
5,867 |
|
|
2,134 |
|
Restricted stock units (1)
|
4,690 |
|
|
— |
|
|
4,690 |
|
|
— |
|
Restricted stock awards (1)
|
250 |
|
|
— |
|
|
250 |
|
|
— |
|
Shares of Class V common stock (2)
|
— |
|
|
494 |
|
|
— |
|
|
494 |
|
| Total |
92,745 |
|
|
13,447 |
|
|
92,745 |
|
|
13,447 |
|
____________________
(1)Represents the number of instruments outstanding at the end of the period. Application of the treasury stock method would reduce this amount if they had a dilutive effect and were included in the computation of diluted net loss per share.
(2)Shares of Class V common stock at the end of the period, including shares tied to unvested Common Units, are considered potentially dilutive shares of Class A common stock under the application of the if-converted method.
|